Syndax Pharmaceuticals IncSNDXEarnings & Financial Report
Syndax Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing innovative oncology therapies for patients with hard-to-treat cancers. Its pipeline includes targeted and immunotherapy candidates addressing unmet medical needs, primarily serving global oncology healthcare stakeholders and patient populations.
SNDX Q4 FY2025 Key Financial Metrics
Revenue
$68.5M
Gross Profit
N/A
Operating Profit
$-62.5M
Net Profit
$-68.0M
Gross Margin
N/A
Operating Margin
-91.3%
Net Margin
-99.3%
YoY Growth
791.7%
EPS
$-0.78
Syndax Pharmaceuticals Inc Q4 FY2025 Financial Summary
Syndax Pharmaceuticals Inc reported revenue of $68.5M (up 791.7% YoY) for Q4 FY2025, with a net profit of $-68.0M (up 27.8% YoY) (-99.3% margin).
Key Financial Metrics
| Total Revenue | $68.5M |
|---|---|
| Net Profit | $-68.0M |
| Gross Margin | N/A |
| Operating Margin | -91.3% |
| Report Period | Q4 FY2025 |
Syndax Pharmaceuticals Inc Annual Revenue by Year
Syndax Pharmaceuticals Inc annual revenue history includes year-by-year totals (for example, 2025 revenue was $172.4M).
Syndax Pharmaceuticals Inc Quarterly Revenue & Net Profit History
Syndax Pharmaceuticals Inc results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $68.5M | +791.7% | $-68.0M | -99.3% |
| Q3 FY2025 | $45.9M | +267.0% | $-60.7M | -132.4% |
| Q2 FY2025 | $38.0M | +984.5% | $-71.8M | -189.3% |
| Q1 FY2025 | $20.0M | — | $-84.8M | -423.3% |
| Q3 FY2024 | $12.5M | — | $-84.1M | -673.0% |
| Q1 FY2024 | $0 | — | $-72.4M | N/A |
| Q3 FY2023 | $0 | — | $-51.1M | N/A |
| Q2 FY2023 | $0 | — | $-44.6M | N/A |
Income Statement
| Q2 2023 | Q3 2023 | Q1 2024 | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $12.5M | $20.0M | $38.0M | $45.9M | $68.5M |
| YoY Growth | N/A | N/A | N/A | N/A | N/A | 984.5% | 267.0% | 791.7% |
Balance Sheet
| Q2 2023 | Q3 2023 | Q1 2024 | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $431.3M | $399.2M | $543.0M | $425.8M | $640.7M | $596.1M | $551.8M | $529.7M |
| Liabilities | $31.3M | $40.0M | $51.1M | $59.4M | $425.6M | $438.7M | $436.4M | $465.1M |
| Equity | $400.0M | $359.2M | $491.9M | $366.4M | $215.1M | $157.4M | $115.4M | $64.6M |
Cash Flow
| Q2 2023 | Q3 2023 | Q1 2024 | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-35.4M | $-44.7M | $-83.5M | $-62.3M | $-95.2M | $-87.8M | $-70.5M | $-69.5M |